Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 Jun;168(2):299-306.
doi: 10.1007/s11060-024-04668-5. Epub 2024 Apr 17.

Exploring management and outcomes of elderly patients with glioblastoma using data from two randomised trials (GEINO1401/EX-TEM)

Lucy Gately #  1   2 , C Mesía  3 , J M Sepúlveda  4 , S Del Barco  5 , E Pineda  6 , R Gironés  7 , J Fuster  8 , M Dumas  9 , S Gill  10 , L M Navarro  11 , A Herrero  12 , A Dowling  13 , R de Las Peñas  14 , M A Vaz  15 , M Alonso  16 , Z Lwin  17 , R Harrup  18 , S Peralta  19 , A Long  20 , P Perez-Segura  21 , E Ahern  22 , C O Garate  23 , M Wong  24 , R Campbell  25 , K Cuff  26 , R Jennens  27 , O Gallego  28 , C Underhill  29   30 , M Martinez-Garcia  31 , M Covela  32 , A Cooper  33 , S Brown  34 , M Rosenthal  35 , J Torres  36 , I M Collins  37 , P Gibbs  9 , C Balana #  38   39
Affiliations
Randomized Controlled Trial

Exploring management and outcomes of elderly patients with glioblastoma using data from two randomised trials (GEINO1401/EX-TEM)

Lucy Gately et al. J Neurooncol. 2024 Jun.

Abstract

Purpose: The impact of age on optimal management of glioblastoma remains unclear. A recent combined analysis of two randomised trials, GEINO14-01 and EX-TEM, found no benefit from extending post-radiation temozolomide in newly diagnosed glioblastoma. Here, we explore the impact of age.

Methods: Relevant intergroup statistics were used to identify differences in tumour, treatment and outcome characteristics based on age with elderly patients (EP) defined as age 65 years and over. Survival was estimated using the Kaplan Meier method.

Results: Of the combined 205 patients, 57 (28%) were EP. Of these, 95% were ECOG 0-1 and 65% underwent macroscopic resection compared with 97% and 61% of younger patients (YP) respectively. There were numerically less MGMT-methylated (56% vs. 63%, p = 0.4) and IDH-mutated (4% vs. 13%, p = 0.1) tumours in EP vs. YP. Following surgery, EP were more likely to receive short course chemoradiation (17.5% vs. 6%, p = 0.017). At recurrence, EP tended to receive or best supportive care (28.3% vs. 15.4%, p = 0.09) or non-surgical options (96.2% vs. 84.6%, p = 0.06), but were less likely to receive bevacizumab (23.1% vs. 49.5%, p < 0.01). Median PFS was similar at 9.3months in EP and 8.5months in YP, with similar median OS at 20months.

Conclusion: In this trial population of predominantly fit EP, survival was similar to YP despite a proportion receiving less aggressive therapy at diagnosis and recurrence. Advancing age does not appear to be an adverse prognostic factor for glioblastoma when patients are fit for treatment, and a less aggressive approach in selected patients may not compromise outcomes.

Keywords: Elderly; Glioblastoma; Prognosis; Survival; Treatment.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Ostrom QT, Patil N, Cioffi G et al (2020) CBTRUS Statistical Report: primary brain and other central nervous system tumours diagnosed in the United States in 2013–2017. Neuro Oncol 22(12 Suppl 2):iv1–iv96 - DOI - PubMed - PMC
    1. Liu Y, Wasilewski A, Mohile NA (2020) Disparities in patient enrollment on glioblastoma clinical trials. CNS Oncol 9(2):CNS59 - DOI - PubMed - PMC
    1. Stupp R, Mason WP, van den Bent MJ, European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996 - DOI - PubMed
    1. Stupp R, Hegi ME, Mason WP, van den Bent MJ, European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459–466 - DOI - PubMed
    1. Malmström A, Grønberg BH, Marosi C et al (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the nordic randomised, phase 3 trial. Lancet Oncol 13:916–926 - DOI - PubMed

Publication types

Substances

LinkOut - more resources